CLINICAL RESEARCH: HEART RHYTHM DISORDER
Bleeding Risk During Oral Anticoagulation in Atrial Fibrillation Patients Older Than 80 Years
Daniela Poli, MD*, ,*,
Emilia Antonucci, MS*,,
Elisa Grifoni, MD*,,
Rosanna Abbate, MD*,,
Gian Franco Gensini, MD*,, and
Domenico Prisco, MD*,
* Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
Department of Heart and Vessels, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
Centro S. Maria agli Ulivi, Fondazione Don Carlo Gnocchi Onlus IRCCS, Impruneta, Florence, Italy
Manuscript received March 13, 2009;
revised manuscript received May 6, 2009,
accepted May 25, 2009.
* Reprint requests and correspondence: Dr. Daniela Poli, Centro di Riferimento Regionale per la Trombosi, Azienda Ospedaliera Universitaria Careggi, V.le Morgagni 85-50134 Firenze, Italy (Email: polida{at}aou-careggi.toscana.it).
Objectives: We sought to evaluate the rate of bleeding in relation to age (<80 and  80 years), the quality of anticoagulation (expressed as time spent in international normalized ratio therapeutic range), and factors associated with bleeding events.
Background: Stroke prevention in patients with atrial fibrillation (AF) is an increasingly crucial public health target, particularly in patients ages 80 years.
Methods: We conducted a prospective observational study on 783 patients with AF on oral anticoagulant treatment (OAT).
Results: Patients spent a median 14%, 71%, and 15% of time below, within, and above the intended therapeutic range, respectively. No difference in OAT quality was found between patients age <80 and 80 years. During follow-up, 94 patients experienced bleeding complications (rate 3.7 x 100 patient/years), 37 major (rate 1.4 x 100 patient/years), and 57 minor (rate 2.2 x 100 patient/years). Different rates of major hemorrhage were observed between patients age <80 and 80 years (0.9 vs. 1.9 x 100 patient/years; p = 0.004). Bleeding risk also was greater in patients with a history of previous cerebral ischemic event (odds ratio [OR]: 2.5; 95% confidence interval: 1.3 to 4.8; p = 0.007). A Cox regression analysis confirmed age 80 years associated with bleeding risk (OR: 2.0).
Conclusions: These results indicate that the rate of major bleeding complications may be kept acceptably low also in very elderly AF patients on OAT, provided a careful management of anticoagulation is obtained.
Key Words: atrial fibrillation • bleeding • elderly • quality of anticoagulation • warfarin
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | CHADS2
= congestive heart failure, age, diabetes, previous stroke | | CI = confidence interval | | INR = international normalized ratio | | OAT = oral anticoagulant treatment | | OR = odds ratio | | TIA = transient ischemic attack |
|
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A26.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. Poli, S. Testa, E. Antonucci, E. Grifoni, O. Paoletti, and G. Y. H. Lip
Bleeding and Stroke Risk in a Real-world Prospective Primary Prevention Cohort of Patients With Atrial Fibrillation
Chest,
October 1, 2011;
140(4):
918 - 924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Poli, E. Antonucci, S. Testa, A. Tosetto, W. Ageno, G. Palareti, and for the Italian Federation of Anticoagulation Clin
Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment: Results of a Prospective Collaborative Study on Elderly Patients Followed by Italian Centres for Anticoagulation
Circulation,
August 16, 2011;
124(7):
824 - 829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Roldan, F. Marin, B. Muina, J. M. Torregrosa, D. Hernandez-Romero, M. Valdes, V. Vicente, and G. Y. H. Lip
Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients
J. Am. Coll. Cardiol.,
June 21, 2011;
57(25):
2496 - 2504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. T. Chen, C. M. White, O. J. Phung, J. Kluger, A. O. Ashaye, D. M. Sobieraj, S. Makanji, V. Tongbram, W. L. Baker, and C. I. Coleman
Association Between CHADS2 Risk Factors and Anticoagulation-Related Bleeding: A Systematic Literature Review
Mayo Clin. Proc.,
June 1, 2011;
86(6):
509 - 521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Y. H. Lip, F. Andreotti, L. Fauchier, K. Huber, E. Hylek, E. Knight, D. A. Lane, M. Levi, F. Marin, G. Palareti, et al.
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis
Europace,
May 1, 2011;
13(5):
723 - 746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Decousus, V. F. Tapson, J.-F. Bergmann, B. H. Chong, J. B. Froehlich, A. K. Kakkar, G. J. Merli, M. Monreal, M. Nakamura, R. Pavanello, et al.
Factors at Admission Associated With Bleeding Risk in Medical Patients: Findings From the IMPROVE Investigators
Chest,
January 1, 2011;
139(1):
69 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Medi, G. J. Hankey, and S. B. Freedman
Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation
Stroke,
November 1, 2010;
41(11):
2705 - 2713.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Marinigh, G. Y. H. Lip, N. Fiotti, C. Giansante, and D. A. Lane
Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications for Thromboprophylaxis
J. Am. Coll. Cardiol.,
September 7, 2010;
56(11):
827 - 837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Rahimtoola
Choice of Prosthetic Heart Valve in Adults: An Update
J. Am. Coll. Cardiol.,
June 1, 2010;
55(22):
2413 - 2426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cowan and E. M. Hylek
Bleeding Risk on Warfarin Among Elderly Patients With Atrial Fibrillation
J. Am. Coll. Cardiol.,
March 2, 2010;
55(9):
932 - 932.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Poli, E. Antonucci, and E. Grifoni
Reply
J. Am. Coll. Cardiol.,
March 2, 2010;
55(9):
932 - 933.
[Full Text]
[PDF]
|
|
|
|
